A Forkhead Box Protein C2 Inhibitor: Targeting Epithelial-Mesenchymal Transition and Cancer Metastasis.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The epithelial-mesenchymal transition (EMT) is crucial for cancer metastasis and stem cell-like properties.
• Forkhead box protein C2 (FOXC2) drives EMT, promoting cancer cell motility, invasiveness, self-renewal, and therapy resistance.
• Targeting EMT transcription factors represents a promising strategy for anti-metastatic cancer therapies.

Purpose of the Study:

• To identify and characterize the first small-molecule inhibitor of FOXC2.
• To evaluate the efficacy of the FOXC2 inhibitor, MC-1-F2, in reversing EMT and inhibiting cancer cell invasion and migration.
• To establish FOXC2 inhibition as a novel therapeutic approach for metastatic cancers.

Main Methods:

• Development of MC-1-F2, a novel small-molecule inhibitor targeting FOXC2.
• Assessment of MC-1-F2's effects on cadherin switching and EMT markers.
• Evaluation of MC-1-F2's impact on FOXC2 degradation and nuclear localization.
• In vitro assays to measure inhibition of cancer cell migration and invasion.

Main Results:

• MC-1-F2 successfully induced cadherin switching, indicating EMT reversal.
• The inhibitor effectively degraded FOXC2 and blocked its nuclear translocation.
• MC-1-F2 significantly inhibited cancer cell migration and invasion in vitro.
• MC-1-F2 represents the first small-molecule inhibitor of FOXC2 and an EMT-associated transcription factor.

Conclusions:

• MC-1-F2 is a potent inhibitor of FOXC2, capable of reversing EMT.
• This novel compound demonstrates significant anti-metastatic potential by inhibiting cancer cell invasion and migration.
• MC-1-F2 offers a promising new therapeutic avenue for treating metastatic cancers and provides a tool to further study EMT signaling pathways.